Works matching DE "LECANEMAB"

Results: 89

Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease.

Published in:

Egyptian Journal of Neurology, Psychiatry & Neurosurgery, 2025, v. 61, n. 1, p. 1, doi. 10.1186/s41983-025-00968-3

By:

Ameen, Taha basit;
Ali, Umair;
Salma, Omme;
Abdul Samee, Muhammad;
Iraj Abbas, Syed Muhammad;
Naveera Kashif, Syeda;
Arif Arifi, Muhammad;
Ali, Mashooque;
Khowaja, Maher;
Sinaan Ali, Syed Muhammad;
Raheem, Abdul

Publication type:

Article

A - 130 Effectiveness of Beta-Amyloid Immunotherapy and Monoclonal Antibodies in Patients with Early Onset Alzheimer's between the Ages of 45–60 Years.

Published in:

Archives of Clinical Neuropsychology, 2024, v. 39, n. 7, p. 1071, doi. 10.1093/arclin/acae067.144

By:

Cortes, Edgar J;
Morant, Rodnie;
Martinez Casiano, Karla D;
Ocasio-Quiñones, Idanara T

Publication type:

Article

A - 116 A Neuropsychological Testing Protocol for Assessing Lecanemab Eligibility for Alzheimer's Disease: the First Fifty Patients.

Published in:

2024

By:

Parks, Adam;
Brunette, Amanda;
Reinhart, Clare;
Kreszyn, Katelynn;
Townley, Ryan;
Burns, Jeffrey

Publication type:

Abstract

Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease.

Published in:

Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-43933-5

By:

Solopova, Elena;
Romero-Fernandez, Wilber;
Harmsen, Hannah;
Ventura-Antunes, Lissa;
Wang, Emmeline;
Shostak, Alena;
Maldonado, Jose;
Donahue, Manus J.;
Schultz, Daniel;
Coyne, Thomas M.;
Charidimou, Andreas;
Schrag, Matthew

Publication type:

Article

Lecanemab‐Associated Amyloid‐β Protofibril in Cerebrospinal Fluid Correlates with Biomarkers of Neurodegeneration in Alzheimer's Disease.

Published in:

Annals of Neurology, 2025, v. 97, n. 5, p. 993, doi. 10.1002/ana.27175

By:

Noguchi‐Shinohara, Moeko;
Shuta, Kazuyoshi;
Murakami, Hidetomo;
Mori, Yukiko;
Komatsu, Junji;
Kobayashi, Chizuru;
Hersch, Steven;
Horie, Kanta;
Ono, Kenjiro

Publication type:

Article

Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease.

Published in:

Annals of Neurology, 2024, v. 95, n. 2, p. 288, doi. 10.1002/ana.26819

By:

Grill, Joshua D.;
Flournoy, Charlene;
Dhadda, Shobha;
Ernstrom, Karin;
Sperling, Reisa;
Molina‐Henry, Doris;
Tranotti, Kate;
Harris, Russell;
Kanekiyo, Michio;
Gee, Michelle;
Irizarry, Michael;
Kramer, Lynn;
Aisen, Paul;
Raman, Rema

Publication type:

Article

Lecanemab-irmb.

Published in:: American Journal of Health-System Pharmacy, 2023, v. 80, n. 9, p. e81, doi. 10.1093/ajhp/zxad033
Publication type:: Article

Lecanemab: First Approval.

Published in:

Drugs, 2023, v. 83, n. 4, p. 359, doi. 10.1007/s40265-023-01851-2

By:

Hoy, Sheridan M.

Publication type:

Article

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease.

Published in:

Alzheimer's Research & Therapy, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13195-022-01129-x

By:

Dhadda, Shobha;
Kanekiyo, Michio;
Li, David;
Swanson, Chad J.;
Irizarry, Michael;
Berry, Scott;
Kramer, Lynn D.;
Berry, Donald A.

Publication type:

Article

Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.

Published in:

Alzheimer's Research & Therapy, 2022, p. 1, doi. 10.1186/s13195-022-01124-2

By:

McDade, Eric;
Cummings, Jeffrey L.;
Dhadda, Shobha;
Swanson, Chad J.;
Reyderman, Larisa;
Kanekiyo, Michio;
Koyama, Akihiko;
Irizarry, Michael;
Kramer, Lynn D.;
Bateman, Randall J.

Publication type:

Article

Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Published in:

2022

By:

Swanson, Chad J.;
Zhang, Yong;
Dhadda, Shobha;
Wang, Jinping;
Kaplow, June;
Lai, Robert Y. K.;
Lannfelt, Lars;
Bradley, Heather;
Rabe, Martin;
Koyama, Akihiko;
Reyderman, Larisa;
Berry, Donald A.;
Berry, Scott;
Gordon, Robert;
Kramer, Lynn D.;
Cummings, Jeffrey L.

Publication type:

Correction Notice

Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Published in:

2022

By:

Swanson, Chad J.;
Zhang, Yong;
Dhadda, Shobha;
Wang, Jinping;
Kaplow, June;
Lai, Robert Y. K.;
Lannfelt, Lars;
Bradley, Heather;
Rabe, Martin;
Koyama, Akihiko;
Reyderman, Larisa;
Berry, Donald A.;
Berry, Scott;
Gordon, Robert;
Kramer, Lynn D.;
Cummings, Jeffrey L.

Publication type:

Correction Notice

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Published in:

2022

By:

Swanson, Chad J.;
Zhang, Yong;
Dhadda, Shobha;
Wang, Jinping;
Kaplow, June;
Lai, Robert Y. K.;
Lannfelt, Lars;
Bradley, Heather;
Rabe, Martin;
Koyama, Akihiko;
Reyderman, Larisa;
Berry, Donald A.;
Berry, Scott;
Gordon, Robert;
Kramer, Lynn D.;
Cummings, Jeffrey L.

Publication type:

Correction Notice

Unraveling Alzheimer's: the promise of aducanumab, lecanemab, and donanemab.

Published in:

Egyptian Journal of Neurology, Psychiatry & Neurosurgery, 2024, v. 60, n. 1, p. 1, doi. 10.1186/s41983-024-00845-5

By:

Ameen, Taha Basit;
Kashif, Syeda Naveera;
Abbas, Syed Muhammad Iraj;
Babar, Kulsoom;
Ali, Syed Muhammad Sinaan;
Raheem, Abdul

Publication type:

Article

Use of lecanemab for the treatment of Alzheimer's disease: A systematic review.

Published in:

Brain & Behavior, 2024, v. 14, n. 6, p. 1, doi. 10.1002/brb3.3592

By:

Hossain, Md Fahad;
Husna, Ashma Ul;
Kharel, Manish

Publication type:

Article

A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer's Disease.

Published in:

CNS Drugs, 2024, v. 38, n. 7, p. 493, doi. 10.1007/s40263-024-01097-w

By:

Rosenbloom, Michael H.;
O'Donohue, Tricia;
Zhou-Clark, Domi;
Mala, Deepashni;
Frazier, Andrew;
Tarrant, Michael;
Modrijan, Michelle;
Riveira, Melora;
Chapman, Darla;
Griffin, Yvonne;
Shakalis, Lauren;
Grabowski, Thomas J.

Publication type:

Article

Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.

Published in:

CNS Drugs, 2024, v. 38, n. 3, p. 169, doi. 10.1007/s40263-024-01067-2

By:

Qiao, Yue;
Gu, Jian;
Yu, Miao;
Chi, Yuewei;
Ma, Ying

Publication type:

Article

알츠하이머병에서 항아밀로이드 단일클론항체 치료제에 의한 아밀로이드 관련 영상 이상: 표준 자기공명영상 프로토콜에 대한 전문가 권고안

Published in:

Journal of the Korean Society of Radiology (2951-0805), 2025, v. 86, n. 1, p. 34, doi. 10.3348/jksr.2024.0147

By:

김지민;
김은희;
박미나;
배윤정;
서종현;
유성혜;
임영희;
이호준;
최진욱;
오세원;
문원진

Publication type:

Article

항-아밀로이드 베타 단일클론 항체 치료에서 발생하는 항-아밀로이드 영상 이상 소견: 영상의학과 의사를 위한 최신 업데이트

Published in:

Journal of the Korean Society of Radiology (2951-0805), 2025, v. 86, n. 1, p. 17, doi. 10.3348/jksr.2024.0140

By:

정소영;
서종현;
임재성;
최양신;
김호성;
김상준;
이재홍

Publication type:

Article

Lecanemab: The Price of a Breakthrough.

Published in:

touchREVIEWS in Neurology, 2023, v. 19, n. 1, p. 14, doi. 10.17925/USN.2023.19.1.14

By:

Wimo, Anders;
Jönsson, Linus;
Johansson, Gunilla;
Winblad, Bengt

Publication type:

Article

Lecanemab's Path Forward: Navigating the Future of Alzheimer's Treatment in Europe Amidst the EMA's Rejection.

Published in:

Neurology & Therapy, 2025, v. 14, n. 1, p. 1, doi. 10.1007/s40120-024-00675-w

By:

Martorana, Alessandro;
Bonomi, Chiara Giuseppina;
Di Donna, Martina Gaia;
Motta, Caterina

Publication type:

Article

Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation.

Published in:

Neurology & Therapy, 2023, v. 12, n. 4, p. 1133, doi. 10.1007/s40120-023-00492-7

By:

Igarashi, Ataru;
Azuma, Mie Kasai;
Zhang, Quanwu;
Ye, Weicheng;
Sardesai, Aditya;
Folse, Henri;
Chavan, Ameya;
Tomita, Kiyoyuki;
Tahami Monfared, Amir Abbas

Publication type:

Article

A Path to Improved Alzheimer's Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer's Disease from the CLARITY AD Trial.

Published in:

Neurology & Therapy, 2023, v. 12, n. 3, p. 863, doi. 10.1007/s40120-023-00473-w

By:

Tahami Monfared, Amir Abbas;
Ye, Weicheng;
Sardesai, Aditya;
Folse, Henri;
Chavan, Ameya;
Aruffo, Elena;
Zhang, Quanwu

Publication type:

Article

Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.

Published in:

Neurology & Therapy, 2023, v. 12, n. 3, p. 795, doi. 10.1007/s40120-023-00460-1

By:

Tahami Monfared, Amir Abbas;
Ye, Weicheng;
Sardesai, Aditya;
Folse, Henri;
Chavan, Ameya;
Kang, Kang;
Zhang, Quanwu

Publication type:

Article

The Potential Economic Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.

Published in:

Neurology & Therapy, 2022, v. 11, n. 3, p. 1285, doi. 10.1007/s40120-022-00373-5

By:

Tahami Monfared, Amir Abbas;
Tafazzoli, Ali;
Chavan, Ameya;
Ye, Weicheng;
Zhang, Quanwu

Publication type:

Article

Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.

Published in:

Neurology & Therapy, 2022, v. 11, n. 2, p. 863, doi. 10.1007/s40120-022-00350-y

By:

Tahami Monfared, Amir Abbas;
Tafazzoli, Ali;
Ye, Weicheng;
Chavan, Ameya;
Zhang, Quanwu

Publication type:

Article

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Published in:

Alzheimer's Research & Therapy, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13195-021-00813-8

By:

Swanson, Chad J.;
Zhang, Yong;
Dhadda, Shobha;
Wang, Jinping;
Kaplow, June;
Lai, Robert Y. K.;
Lannfelt, Lars;
Bradley, Heather;
Rabe, Martin;
Koyama, Akihiko;
Reyderman, Larisa;
Berry, Donald A.;
Berry, Scott;
Gordon, Robert;
Kramer, Lynn D.;
Cummings, Jeffrey L.

Publication type:

Article

Lecanemab: A Hopeful Alzheimer's Disease Treatment.

Published in:

Annals of Neurosciences, 2024, v. 31, n. 2, p. 83, doi. 10.1177/09727531231189925

By:

Mughal, Zaib Un Nisa;
Ahmed, Bisma;
Amin, Fatima;
Sadiq, Aiman;
Rangwala, Burhanuddin Sohail

Publication type:

Article

Mechanism of action and clinical trial results of Lecanemab (Leqembi® 200 mg, 500 mg for Intravenous Infusion), a novel treatment for Alzheimer's disease.

Published in:

Folia Pharmacologica Japonica, 2024, v. 159, n. 3, p. 173

By:

Tetsuhiro Niidome;
Yukio Ishikawa;
Tomoo Ogawa;
Masaki Nakagawa;
Yosuke Nakamura

Publication type:

Article

Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment.

Published in:

Inflammation Research, 2023, v. 72, n. 9, p. 1873, doi. 10.1007/s00011-023-01788-y

By:

Zhang, Jinwei

Publication type:

Article

Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial.

Published in:

JAMA Network Open, 2023, v. 6, n. 4, p. e237230, doi. 10.1001/jamanetworkopen.2023.7230

By:

Berry, Donald A.;
Dhadda, Shobha;
Kanekiyo, Michio;
Li, David;
Swanson, Chad J.;
Irizarry, Michael;
Kramer, Lynn D.;
Berry, Scott M.

Publication type:

Article

The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.

Published in:

Neurological Sciences, 2024, v. 45, n. 8, p. 3583, doi. 10.1007/s10072-024-07477-w

By:

Abdelazim, Karim;
Allam, Ahmed A.;
Afifi, Badreldin;
Abdulazeem, Hebatullah;
Elbehiry, Ahmed I.

Publication type:

Article

Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG.

Published in:

Annals of Clinical & Translational Neurology, 2024, v. 11, n. 12, p. 3192, doi. 10.1002/acn3.52227

By:

Bellier, Jean‐Pierre;
Román Viera, Andrea M.;
Christiano, Caitlyn;
Anzai, Juliana A. U.;
Moreno, Stephanie;
Campbell, Emily C.;
Godwin, Lucas;
Li, Amy;
Chen, Alan Y.;
Alam, Sarah M.;
Saba, Adriana;
Yoo, Han Bin;
Yang, Hyun‐Sik;
Chhatwal, Jasmeer P.;
Selkoe, Dennis J.;
Liu, Lei

Publication type:

Article

Population pharmacokinetics and exposure–response analyses of safety (ARIA‐E and isolated ARIA‐H) of lecanemab in subjects with early Alzheimer's disease.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 12, p. 2111, doi. 10.1002/psp4.13224

By:

Majid, Oneeb;
Cao, Youfang;
Willis, Brian A.;
Hayato, Seiichi;
Takenaka, Osamu;
Lalovic, Bojan;
Sreerama Reddy, Sree Harsha;
Penner, Natasha;
Reyderman, Larisa;
Yasuda, Sanae;
Hussein, Ziad

Publication type:

Article

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 12, p. 1578, doi. 10.1002/psp4.12862

By:

Hayato, Seiichi;
Takenaka, Osamu;
Sreerama Reddy, Sree Harsha;
Landry, Ishani;
Reyderman, Larisa;
Koyama, Akihiko;
Swanson, Chad;
Yasuda, Sanae;
Hussein, Ziad

Publication type:

Article

Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective.

Published in:

British Journal of Clinical Pharmacology, 2025, v. 91, n. 5, p. 1352, doi. 10.1002/bcp.70021

By:

Bobbins, Amy;
Davies, Miranda;
Lynn, Elizabeth;
Roy, Debabrata;
Yeomans, Alison;
Shakir, Saad A. W.

Publication type:

Article

Lecanemab: The advent of biologicals in Alzheimer's disease, affordability, and clinical relevance.

Published in:

Journal of Applied Pharmaceutical Science, 2025, v. 15, n. 3, p. 30, doi. 10.7324/JAPS.2025.204843

By:

Anil, Aswin A.;
Krishnan, Aishwarya Laxmi;
Chandra, Prashant;
Unnikrishnan, Mazhuvanchery Kesavan

Publication type:

Article

Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.

Published in:

Clinical Pharmacology & Therapeutics, 2023, v. 114, n. 3, p. 614, doi. 10.1002/cpt.2954

By:

Dhruva, Sanket S.;
Kesselheim, Aaron S.;
Woloshin, Steven;
Ji, Robin Z.;
Lu, Zhigang;
Darrow, Jonathan J.;
Redberg, Rita F.

Publication type:

Article

Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?

Published in:

International Journal of Molecular Sciences, 2024, v. 25, n. 7, p. 3892, doi. 10.3390/ijms25073892

By:

Høilund-Carlsen, Poul F.;
Alavi, Abass;
Castellani, Rudolph J.;
Neve, Rachael L.;
Perry, George;
Revheim, Mona-Elisabeth;
Barrio, Jorge R.

Publication type:

Article

Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.

Published in:

International Journal of Molecular Sciences, 2023, v. 24, n. 18, p. 13900, doi. 10.3390/ijms241813900

By:

Buccellato, Francesca R.;
D'Anca, Marianna;
Tartaglia, Gianluca Martino;
Del Fabbro, Massimo;
Scarpini, Elio;
Galimberti, Daniela

Publication type:

Article

FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 6, p. 1553, doi. 10.1007/s00259-023-06177-5

By:

Verger, Antoine;
Yakushev, Igor;
Albert, Nathalie L.;
van Berckel, Bart;
Brendel, Matthias;
Cecchin, Diego;
Fernandez, Pablo Aguiar;
Fraioli, Francesco;
Guedj, Eric;
Morbelli, Silvia;
Tolboom, Nelleke;
Traub-Weidinger, Tatjana;
Van Weehaeghe, Donatienne;
Barthel, Henryk

Publication type:

Article

Eisai Presents Real-World Lecanemab Data at AD/PD 2025 Confirming Phase 3 Clinical Trial Findings.

Published in:

Patient Care (Online), 2025, p. N.PAG

By:

Halsey, Grace

Publication type:

Article

Eisai Will Highlight Real-World Experience Data with Lecanemab at 2025 American Academy of Neurology Meeting.

Published in:

2025

By:

Halsey, Grace

Publication type:

Proceeding

FDA Approves Monthly Lecanemab for Early-Stage Alzheimer Disease: Daily Dose.

Published in:

Patient Care (Online), 2025, p. 1

By:

Jennings, Sydney

Publication type:

Article

Patient Selection for Lecanemab to Treat Early Alzheimer Dementia: Details with R Scott Turner, PhD, MD.

Published in:

Patient Care (Online), 2025, p. 1

By:

Turner, R. Scott

Publication type:

Article

Lecanemab Monthly IV Maintenance Dosing: Research Highlights with R Scott Turner, PhD, MD.

Published in:

Patient Care (Online), 2025, p. 5

By:

Turner, R Scott

Publication type:

Article

FDA Approves Monthly IV Maintenance Dosing of Lecanemab for Adults with Early Alzheimer Dementia: A First in Long-Term Disease Management.

Published in:

Patient Care (Online), 2025, p. 2

By:

Halsey, Grace

Publication type:

Article

Anti-Amyloid Antibodies in Short: R Scott Turner, PhD, MD Explains.

Published in:

Patient Care (Online), 2025, p. 5

By:

Turner, R. Scott

Publication type:

Article

European Medicines Agency Reverses Opinion on Lecanemab for Alzheimer Disease But Limits Eligible Population.

Published in:

Patient Care (Online), 2024, p. 9

By:

Halsey, Grace

Publication type:

Article

New Phase 3 Data Suggest Benefits of Early Lecanemab Initiation on Alzheimer Disease Progression, Support Long-Term Safety.

Published in:

Patient Care (Online), 2024, p. 2

By:

Halsey, Grace

Publication type:

Article